The Challenge of Reducing Complexity of Heart Failure Treatment Without Losing Efficacy: Quo Vadis?
- PMID: 35926932
- DOI: 10.1016/j.jacc.2022.05.028
The Challenge of Reducing Complexity of Heart Failure Treatment Without Losing Efficacy: Quo Vadis?
Keywords: chronic heart failure; heart rate; ivabradine; systolic dysfunction.
Conflict of interest statement
Funding Support and Author Disclosures Dr Bocchi has received consulting fees from Servier, AstraZeneca, and Boehringer Ingelheim; has received subsidized travel/hotel/registration fees from Servier; has served on the Steering Committee of Novartis and Boehringer Ingelheim; has received research grant support through the Heart Institute (Incor) from Janssen, Bayer/Merck, AstraZeneca, Boehringer Ingelheim, and Verdemed; and has received honoraria from Servier, AstraZeneca, and Boehringer Ingelheim. Dr Lima has reported that she has no relationships relevant to the contents of this paper to disclose.
Comment on
-
Sustained-Release Ivabradine Hemisulfate in Patients With Systolic Heart Failure.J Am Coll Cardiol. 2022 Aug 9;80(6):584-594. doi: 10.1016/j.jacc.2022.05.027. J Am Coll Cardiol. 2022. PMID: 35926931 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical